Patents by Inventor Lars Christian Petersen

Lars Christian Petersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of FVIIa or a tissue factor antagonist for regulating gene expression and cell migration or chemotaxis
    Publication number: 20020193302
    Abstract: The present invention relates to use of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to cell migration or treated by specific regulation of cell migration or chemotaxis. The invention also relates to the use of of FVII and/or FVIIa and/or another TF agonist and/or FVIIai and/or another TF antagonist in therapeutic treatment of pathological conditions that can be related to regulation of expression of at least one gene in a cell, e.g., Cyr61 gene.
    Type: Application
    Filed: January 14, 2002
    Publication date: December 19, 2002
    Inventors: Mirella Ezban, Lars Christian Petersen, Agneta Siegbahn
  • Methods for modifying cell motility using factor VIIa or inactivated factor VIIa
    Patent number: 6461610
    Abstract: The present invention provides methods for modifying the motility of tissue factor (TF)-expressing cells, which are carried out by contacting such cells with an effective amount of Factor VIIai Factor VIIa agonist.
    Type: Grant
    Filed: August 12, 1999
    Date of Patent: October 8, 2002
    Assignee: Novo Nordisk A/S
    Inventors: Lars Kongsbak, Niels Bergenhem, Lars Christian Petersen, Ole Thastrup, Don Foster, Mirella Ezban, Agneta Siegbahn
  • Identification of drug candidates modulating factor VII-mediated intracellular signaling
    Patent number: 6268163
    Abstract: The present invention provides methods for identifying candidate drugs that modulate factor VIIa-mediated intracellular signaling by measuring the effects of such drugs on the activation of the mitogen-activated protein kinase (MAP kinase) signaling pathway.
    Type: Grant
    Filed: July 16, 1998
    Date of Patent: July 31, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Lars Kongsbak, Niels Bergenhem, Lars Christian Petersen, Ole Thastrup, Don Foster
  • Modified factor VII
    Patent number: 6168789
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.
    Type: Grant
    Filed: November 10, 1998
    Date of Patent: January 2, 2001
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
  • Modified Factor VII
    Patent number: 6039944
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: March 21, 2000
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
  • Modified Factor VII
    Patent number: 5861374
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modification renders Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
    Type: Grant
    Filed: February 12, 1996
    Date of Patent: January 19, 1999
    Assignees: Novo Nordisk A/S, ZymoGenetics, Inc.
    Inventors: Kathleen L Berkner, Lars Christian Petersen, Charles E. Hart
  • Factor VII -binding reagent
    Patent number: 5859010
    Abstract: The invention relates to novel compounds that potentiate zinc ion inhibition of the activity of factor VIIa or tissue factor--factor VIIa complex having the formula Ia and Ib and pharmaceutical salts thereof as well as pharmaceutical compositions comprising said novel compounds. The invention is further related to the use of said compositions for inhibiting clotting activity, tissue factor activity and factor VIIa activity.
    Type: Grant
    Filed: June 23, 1997
    Date of Patent: January 12, 1999
    Assignee: Novo Nordisk A/S
    Inventors: Lars Christian Petersen, Ole Hvilsted Olsen, Stefan Lutz Richter, Palle Jakobsen
  • Modified factor VII
    Patent number: 5833982
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.
    Type: Grant
    Filed: June 7, 1996
    Date of Patent: November 10, 1998
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
  • Modified factor VII
    Patent number: 5817788
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
    Type: Grant
    Filed: October 24, 1994
    Date of Patent: October 6, 1998
    Assignees: ZymoGenetics, Inc., Novo Nordisk A/S
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
  • Modified factor VII
    Patent number: 5788965
    Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 4, 1998
    Assignees: Novo Nordisk A/S, ZymoGenetics, Inc.
    Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard